IMV Inc.

Clinical stage biotech developing a portfolio of immune-educating therapies based on our DPX® platform to treat solid and hematological cancers

[IMV Inc. @imv_inc]

Our team is attending the @AACR annual meeting and is presenting today a poster about the diverse and active anti-tumor response generated by MVP-S, our lead #CancerVaccine, in women with advanced recurrent #OvarianCancer. See the poster on our website: https://t.co/8pyXkkPGJD

[IMV Inc. @imv_inc]

Today is #HealthDay. We want to recognize the 75th anniversary of the @WHO. It is an opportunity to look back at health successes that have improved quality of life during the last seven decades. Join us on the journey to achieve #HealthForAll https://t.co/CvfCVWGhJq

#WHO75

[IMV Inc. @imv_inc]

Our lead product has demonstrated durable #ClinicalBenefit in patients with recurrent #OvarianCancer. Click on the link to read the poster that Dr. Dorigo, lead investigator and Professor at the @StanfordMed, presented at the @SGO_org meeting. #SGOMtg

https://t.co/NktMDt8oZ8

[IMV Inc. @imv_inc]

Meet our team at the 2023 @AACR annual meeting in Orlando, FL. We look forward to discussing the latest research in #CancerVaccine with industry peers. Learn about this major conference here: https://t.co/k2sKI5CXR3

#AACR23

[IMV Inc. @imv_inc]

Our DPX platform is a #versatile technology that #delivers cargo into the lymphatic nodes without leakage into non-target tissue allowing for a complete and efficient #vaccine response with limited side effects. Watch the video to learn more about its MOA. https://t.co/P2MCA83PlB

[IMV Inc. @imv_inc]

If you have not yet listened to our #FourthQuarter earnings call, a replay is available on our website: https://t.co/EXsP0hJfni

[IMV Inc. @imv_inc]

Today, we announce strategic updates, and we are hosting our #FourthQuarter and full-year 2022 earnings call and webcast. Read the press release to get further details. The link to register for the webcast is enclosed. https://t.co/zwi49WXX2m

[IMV Inc. @imv_inc]

This Thursday, our management will give its annual fourth quarter and year-end #EarningsCall and webcast. Register and get their perspective on our latest news, where we stand today and what to expect in the next months.

https://t.co/EXsP0hJNcQ

[IMV Inc. @imv_inc]

We are celebrating all the impressive, talented IMV #women today on #InternationalWomensDay and their contribution to pioneering tomorrow’s therapies against #cancer! Learn more about our leadership team here: https://t.co/4GpgYRHcVT

[IMV Inc. @imv_inc]

#ThrowbackThursday - One year ago, we held a #R&Dday webinar describing the science behind our DPX® technology and MVP-S, our DPX-based lead #CancerVaccine. Watch the replay here to learn more about what makes our delivery platform unique: https://t.co/5qrcqvNWuY

[IMV Inc. @imv_inc]

We are happy to announce positive initial results from our VITALIZE Phase 2B #ClinicalStudy in patients with relapse, refractory Diffuse Large B Cell Lymphoma (#DLBCL).

Read more details in our press release: https://t.co/1jIvFr7S9f

[IMV Inc. @imv_inc]

@thomcalandra @LGChemESS @MerckHealthcare @lymphoma @NOCC_National To get our latest official news, please refer to our website: https://t.co/1jIvFr7S9f

[IMV Inc. @imv_inc]

Today, we recognize the International Day of Women and Girls in Science, implemented by @UNESCO and @UN-Women. This Day is an opportunity to promote full and #equalaccess to and participation in science for #women and #girls.

https://t.co/BNzUXClyyr

[IMV Inc. @imv_inc]

This year’s theme marks the second year of the @WHOEMRO campaign #CloseTheCareGap,” which is about understanding the inequities in #cancer care and taking actions to address them. Read more about these actions here: https://t.co/UgIv9qAYCG

[IMV Inc. @imv_inc]

Our CSO Dr. Jeremy Graff, will present at the #IO360 conference. Jeremy will describe the unique immune-educating capability of our DPX platform and give updates on patients' responses - including complete responses, in our #ClinicalTrials evaluating our lead asset, MVP-S.

[IMV Inc. @imv_inc]

Dr. Stanton, medical oncologist @Providence #Cancer Institute, discusses efforts to improve the responses to #immunotherapy regimens in early-stage HR+ #breastcancer. The PhI trial evaluates our lead compound (MVP-S) as a #neoadjuvant therapy. @OncLive

https://t.co/w8yR3uXLBn

[IMV Inc. @imv_inc]

Meet with our CEO, @AndrewHallIMV, and @Delphinedavan, our head of Investor Relations, at the 2023 BIO CEO & Investor Conference in New York City.

@Iambiotech
#InvestorRelations #CEO #BIOCEO2023

[IMV Inc. @imv_inc]

Our team looks forward to attending the Immuno-Oncology 360° Conference again. Meet with Jeremy Graff, our Chief Scientific Officer, and discuss potential partnership and investment opportunities with Genevieve Weir and @Delphinedavan.

[IMV Inc. @imv_inc]

#TBT When IMV was ImmunoVaccine and DPX...DepoVax! The name of our versatile #DeliveryPlatform has changed, but its unique mechanism of action remains the same and is now validated as viable mechanism to enhance the delivery of therapeutic #CancerVaccines: https://t.co/rffvVYtwNj

[IMV Inc. @imv_inc]

We are happy to welcome Ms.
@Shabnam_Kazmi to our #BoardOfDirectors. Shabnam has a track record of delivering revenue upside and leading joint ventures and complex projects. Read her complete bio on our website: https://t.co/p2gCPNvQBr